Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIA trial in HR-positive/HER2-negative metastatic breast cancer
NL-OMON53036Phase 3Completed
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib, ribociclib, abemaciclib, letrozole, anastrozole and 1 more in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-free survival after two lines of treatment. Started Nov 2017; status: completed.
02
Drugs
palbociclibribociclibabemaciclibletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON53036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53036.